The therapeutic landscape for AD has remained relatively static over the past two decades, predominantly relying on second-generation AChE inhibitors such as donepezil, rivastigmine, and galantamine, all of which were approved between 1997 and 2001. The gene discussed is ACHE; the disease is Alzheimer disease.